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Background: It is uncertain whether bleeding after cardiac surgery is associated with mortality, and few studies have examined the extent and 
type of bleeding which may be implicated, nor the proportion of deaths attributable to bleeding. We therefore examined the 1-year results from 
ACUITY, a large-scale trial of pts with acute coronary syndromes (ACS) in whom 1,491 pts underwent coronary artery bypass graft surgery (CABG) 
before hospital discharge.
Methods: Major bleeding was adjudicated by an independent committee as CABG- or non CABG-related. The relationship between CABG-related 
bleeding and subsequent mortality was determined in a time-updated covariate adjusted multivariable analysis.
Results: Major CABG-related bleeding after surgery occurred in 789 pts (52.9%); blood product transfusions were administered in 612 pts (41.0%, 
including red blood cell (RBC) transfusions in 570 pts (38.2%, range 1-53 units) and platelet transfusions in 180 pts (12.3%); and 1-year mortality 
occurred in 95 pts (6.4%). As shown in the table, RBC transfusion (but not platelet transfusion nor major bleeding by itself) was an independent 
predictor of mortality, but only after transfusion of ≥4 units. Of the 95 deaths after CABG, 27 (28.4%) were attributed to CABG-related transfusions.
Conclusions: RBC transfusion of ≥4 units after CABG is an important contributor to death in pts with ACS requiring surgery. Future strategies must 
focus on reducing major hemorrhagic complications and RBC transfusions after CABG. 
